Ask AI
ProCE Banner Activity

Year in Review in EGFR-Mutated NSCLC: Treatment Strategies for 2L+ and Exon 20 Insertions

Slideset

Downloadable slides on recent advances, biomarker testing trends, treatment strategies, and emerging therapies for advanced EGFR-mutated NSCLC, including EGFR exon 20 insertion.

Released: May 22, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by an educational grant from Johnson & Johnson.

 

Johnson & Johnson

Target Audience

This educational activity is intended for oncologists, pathologists, and other health care professionals who identify, treat, and manage patients with locally advanced EGFRm non-small lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate current guideline-based recommendations to select appropriate biomarker testing strategies for patients with suspected or confirmed EGFR-mutated NSCLC, including less common alterations

  • Design individualized treatment plans for patients with EGFR exon 19 or 21 alterations in the perioperative and metastatic settings by integrating the latest clinical trial data and guideline-endorsed sequencing strategies

  • Evaluate and compare the safety profiles, efficacy, and treatment burden of first-line regimens to guide shared decision-making aligned with patient preferences and risk features

  • Incorporate the latest clinical evidence on novel and emerging therapies into treatment decisions for patients with EGFR exon 20 insertions or other non-classical EGFR mutations

  • Adapt management strategies for patients with acquired resistance to EGFR TKIs by assessing biomarker-driven mechanisms and selecting subsequent lines of therapy supported by trial-based evidence and expert consensus